On March 5, 2020 Immunowake Inc. reported that it has entered into agreements with Genescience Pharmaceuticals Co., Ltd and Genscript Biotech Corp (HKG: 1548) in which Immunowake will obtain exclusive licenses to PD-L1 antibodies for the development of multi-target therapeutics. Terms of the agreement were not disclosed (Press release, Immunowake, MAR 5, 2020, View Source [SID1234656119]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immunowake is a pre-clinical company focused on the development of antibody-based therapeutics against cancer. Immunowake’s CEO and founder Xiaoyun Wu said, "This agreement provides us the necessary resources to continue to pursue multiple, non-exclusive research collaborations, as well as future financing opportunities."